Objective: To evaluate late effects concerning growth and endocrine function in children and adolescents after stem cell transplantation (SCT). Patients and Methods: 318 patients treated with SCT from 1996 to 1999 were investigated for late effects. The underlying diseases were ALL 21%, AML 13%, CML 7%, MDS 8%, lymphoma 4%, SAA 8%, NB 11%, solid tumours 15% and others 13%. They were followed-up according to a standardised protocol: determination of weight, height (HT), sitting height, leg length, arm-span, head circumference and pubertal status. Analysis of TSH, T4 and fT4, LH, FSH, estradiol and testosterone, in addition, TRH and GnRH testing was performed. Evaluation of the GH axis included measurement of IGF-I and IGFBP-3 and an arginine test. Patients were examined before SCT and 3, 6, 12, 24, 36 months after SCT. Results: HT-SDS before SCT was significantly, p Ͻ 0.005, reduced compared to target HT (n = 145) at -0.52 SDS (median) (range -4.02 to 2.71) versus 0.11 SDS (-2.43 to 2.18). HT-SDS significantly decreased further to -0.67 SDS (-5.03 to 2.94), p Ͻ 0.05, and -1.03 SDS (-4.17 to 0.16), p Ͻ 0.05, after 24 and 36 months. IGF-I and IGFBP-3 had no predictive value for changes in HT-SDS. Individual changes in HT-SDS ranged from -2.02 to 1.93 after 12 to 36 months. Before SCT, primary hypothyroidism was seen in 13.4% (23/172) and after SCT in 18.7% (44/235). Central hypothyroidism was suspected in 64.4% (96/149) with low values for fT4 and/or T4 and a 'normal' TSH. This was confirmed by low TSH peaks in 21% (25/119) of the TRH tests. After SCT, 64.9% (124/191) had low fT4 and/or T4 levels and a 'normal' TSH. Hypergonadotropic hypogonadism was detected in 21.9% (14/64) female (f) and 14.2% (15/106) male (m) patients before SCT. GnRH tests, however, revealed a much higher rate of gonadal dysfunction: 50.0% (32/64) and 21.6% (23/147), respectively. Longitudinal data in 28 f and 45 m patients showed normal LH/FSH levels before and elevated levels after SCT in 28.6% f and 18.0% m patients. Conclusions: Growth failure and endocrine deficiencies are very frequent after SCT. The right diagnostic tools have to be applied for detection of developing dysfunction. The time and order of their occurrence cannot be predicted. To ensure normal growth and development each patient has to be followed individually. Investigations must be performed according to a standardised protocol with co-operation of the paediatric haematologist and the paediatric endocrinologist. Objectives : to analyze the possibility of preservation of fertility in a population of young women treated with high-dose chemotherapy for high-risk aggressive non Hodgkin's lymphomas (NHL). Methods : From 10/87 to 02/93, 916 patients with a median follow-up of 8 years were enrolled in the LNH 87-2 study (Haioun, J Clin Oncol 1997 ;15 :1131.). Briefly, patients with newly diagnosed NHL were treated with chemotherapy A(N)CVBP, 4 cycles and responding patients were randomized between a sequential chemotherapeutic consolidation or a consolidative CBV regimen followed by autologous bone marrow transplantation(ABMT). Total dose of cyclophosphamide (the main toxic drug for ovarian failure) was at 10 800 mg/m 2 at the end of the procedure for the patients treated in the intensive arm with ABMT. Among patients included in the LNH87-2 protocol, we found 210 women under 41 years at diagnosis (evaluable for fertility) from whom 51 had received the intensive arm (median age : 27 years, range 15 to 40 years). Results : 9 patients were reported to have been pregnant at the last follow-up evaluation (12/99). The median time between ABMT and delivery was at 65 months [26 to 108 mo.] and 3 women had 2 pregnancies (including one in utero death). Their mean age at NHL diagnosis was at 23 years [17 to 29 yrs] and no pregnancy was reported in women over 30 yrs at first exposition to alkylating agents. Among the 9 patients with pregnancies only one patient relapsed, received further treatment and died, the remaining 8 women had received only one line of chemotherapy including the CBV and remained alive. One further woman aged 30 at diagnosis needed hormonal replacement therapy after ABMT but delivered 2 healthy children (at 60 and 84 months post ABMT) after prior embryo cryopreservation. Conclusion : high-dose therapy and ABMT has improved the cure rate of high-risk NHL and despite intensive regimens including cyclophosphamide the possibility of retaining fertility remains in women under 30 yrs at diagnosis. For the remaining women who wish to be pregnant after treatment, other chemotherapeutic regimens including lower dose of cyclophosphamide could be discussed until the current availibility of oocytes cryopreservation. Quality of life (QOL) should be one of the most important arguments to be considered in the late follow-up in malignant haematological diseases treated with allogeneic BM or PBPC transplantation mainly due to high incidence and severity of cGVHD. From 1995 to 1999, 56 evaluable randomised patients (pts) were analysed through several dominions comparing BM versus PBPC graft. 30/56 (53.5%) patients are alive. 27/30 (90%) agreed to participate, 15 (56%) males, 12 (44%) females, median age 36 (19-61) and 13 (48%) and 14 (52%) among PBPC and BM groups, respectively. The median survival time was 1123 days for PBPC and 1372 days (384-1942) for BM pts. We applied 4 self-report questionnaires to identify correlates of survivors·quality of life and behavioral adjustment. Considering social, demographic, clinical & QOL we found difference S19
Objectives : to analyze the possibility of preservation of fertility in a population of young women treated with high-dose chemotherapy for high-risk aggressive non Hodgkin's lymphomas (NHL). Methods : From 10/87 to 02/93, 916 patients with a median follow-up of 8 years were enrolled in the LNH 87-2 study (Haioun, J Clin Oncol 1997 ; 15 :1131.) . Briefly, patients with newly diagnosed NHL were treated with chemotherapy A(N)CVBP, 4 cycles and responding patients were randomized between a sequential chemotherapeutic consolidation or a consolidative CBV regimen followed by autologous bone marrow transplantation(ABMT). Total dose of cyclophosphamide (the main toxic drug for ovarian failure) was at 10 800 mg/m 2 at the end of the procedure for the patients treated in the intensive arm with ABMT. Among patients included in the LNH87-2 protocol, we found 210 women under 41 years at diagnosis (evaluable for fertility) from whom 51 had received the intensive arm (median age : 27 years, range 15 to 40 years). Results : 9 patients were reported to have been pregnant at the last follow-up evaluation (12/99). The median time between ABMT and delivery was at 65 months [26 to 108 mo.] and 3 women had 2 pregnancies (including one in utero death). Their mean age at NHL diagnosis was at 23 years [17 to 29 yrs] and no pregnancy was reported in women over 30 yrs at first exposition to alkylating agents. Among the 9 patients with pregnancies only one patient relapsed, received further treatment and died, the remaining 8 women had received only one line of chemotherapy including the CBV and remained alive. One further woman aged 30 at diagnosis needed hormonal replacement therapy after ABMT but delivered 2 healthy children (at 60 and 84 months post ABMT) after prior embryo cryopreservation. Conclusion : high-dose therapy and ABMT has improved the cure rate of high-risk NHL and despite intensive regimens including cyclophosphamide the possibility of retaining fertility remains in women under 30 yrs at diagnosis. For the remaining women who wish to be pregnant after treatment, other chemotherapeutic regimens including lower dose of cyclophosphamide could be discussed until the current availibility of oocytes cryopreservation. Quality of life (QOL) should be one of the most important arguments to be considered in the late follow-up in malignant haematological diseases treated with allogeneic BM or PBPC transplantation mainly due to high incidence and severity of cGVHD. From 1995 to 1999, 56 evaluable randomised patients (pts) were analysed through several dominions comparing BM versus PBPC graft. 30/56 (53.5%) patients are alive. 27/30 (90%) agreed to participate, 15 (56%) males, 12 (44%) females, median age 36 (19-61) and 13 (48%) and 14 (52%) among PBPC and BM groups, respectively. The median survival time was 1123 days for PBPC and 1372 days (384-1942) for BM pts. We applied 4 self-report questionnaires to identify correlates of survivors·quality of life and behavioral adjustment. Considering social, demographic, clinical & QOL we found difference statisticals in dry eyes (P=0.05), extensive cGVHD (P=0.01), and in the period of cGVHD treatment with a median of 270 days in 5/14 BM pts and 570 days in 10/13 PBPC pts (P=0.03). Overall results in the dominions from WHO-QOL-100 have not demonstrated difference significant. However, in the individual facets from WHO-QOL, PBPC pts referred more pain and discomfort (P=0.02), problems in health and social care areas (P=0.05) and mobility (P=0.06). In the anxiety and depression scale (HAD scale) there was no difference. Based on generic questionnaire (Haberman, 1993) , 8/13 (61%) PBPC pts and 6/14 (43%) BM pts, had dissatisfaction in their daily life routine with a median of follow up of 845 days after BMT. Adjusted pts to the daily life routine presented a median of 1566 days after BMT (P=0.0003). 8/27 (30%) pts believed that their life had worsened 6 (46%) in PBPC and 2 (14%) in BM group. Among these patients, seven presented extensive cGVHD. In spite of the small sample, our finding suggest PBPC transplantation may lead to more harms in some important areas of patients·life. The occurrence of leukemia or myelodysplasia in donor cells (DCL) after allogeneic transplantation is only rarely described, but according to recent reports the impression raised that DCL might be more common. To evaluate the frequency, diagnosis, characteristics and treatment options of DCL a questionnaire evaluation within the EBMT was performed. 85 centers responded till now and a total of 6 cases of DCL were identified. None of these cases was previously published. 4 of the 6 cases were AML (primary diagnosis: AML 2, CML 1, SAA 1), one ALL (prim. diagn. AML) and one was an MDS developing into AML (prim. diagn. AML). The donor cell origin of the "new" leukemia was demonstrated by cytogenetic analysis (n=2, 46XX karyotype of leukemia in male patient transplanted from his sister; 46 XY karyotype with multiple anomalies in a female patient transplanted from her brother), by VNTR analysis (n=2) and by cytogenetics + VNTR analysis (n=2). Donor cell origin of the leukemia was judged as proven by 5 and as suspected by one center. Median age of the patients at diagnosis of DCL was 34 ys. (13-44). The interval between SCT and diagnosis of DCL ranged between 8 month and 14 years. The allografts were BM in 5 and PBPC in one case. In 5 cases the donors were HLA-identical siblings, in one patient DCL occurred after transplantation from a matched unrelated donor. The occurrence of leukemia in the donors was not seen in any case. 4 patients received CsA and MTX and 2 patient CsA alone for GvHD-prophylaxis. One patient received 6 doses of intrathecal MTX after transplant, one patient was treated with foscarnet for recurrent CMV infection. No additional treatment with cytotoxic drugs was reported in the other patients. All patients received treatment for their DCL. One patient died of the complications of conventional chemotherapy, one patient died of progressive disease after chemotherapy, two patients died after second transplant from the same donor and two patients are alive 2 and 12 months after a second transplant from an alternative sibling and unrelated donor, respectively. From this data it can be concluded that DCL is an extremely rare event after allogeneic SCT. However, treatment of this complication with conventional chemotherapy and retransplantation might be successful. The increasing number of patients who experience long-term survival after bone marrow transplantation has risen the incidence of late complications, as avascular necrosis (AVN) of bone. Between June 1985 and April 2000, 531 children, aged 3 month-18 years, were transplanted for haematological and non haematological malignancies. Three hundred and eighty-one pts underwent autologous stem cell transplantation, 51 pts were given an unrelated donor (UD), while 98 received related donor Bone Marrow Transplantation (BMT). Eleven pts, 3 males and 8 females, developed symptomatic AVN. For these patients the diseases leading to BMT included AML (1), Aplastic Anaemia (2), ALL (5), MDS (1), Lymphoma (1), CML (1). Six out of these 11 pts received an UD-BMT, 4 a related donor BMT, and only one child underwent autologous BMT. At transplant, patients' median age was 10 years and 8 months. Nine children are alive while two died for transplant related mortality (TRM), at 19 months and 5 years after BMT, respectively. The incidence of AVN in our series of long-survival children undergoing UD BMT, related BMT and autologous BMT is 19.2%, 5.7% and 0.2%, respectively. All but one patient received steroids and cyclosporine for acute or chronic GVHD for a mean period of 26 months (3 months -5 years). Chronic GVHD was present at time of diagnosis in 8 patients. Recipients developed symptoms, as hips and leg pain at a mean of 12 months (range 1 -24 months) after transplantation. Initial standard radiographs detected AVN in one or both femoral heads in 10 cases. In one patient AVN was detected in femoral condyle. Follow-up was carried out with the help of both technetium-99 scan and Magnetic Resonance Imaging (MRI) in 6 pts, while in one case MRI alone was performed. Three out of nine pts underwent O2 Hyperbaric treatment for about one year without any improvement. Two pts required joint replacement 10 and 3 years after BMT, at the age of 24 and 18 years, respectively, with excellent results and without any complication. Three pts are still under combined treatment with Calcium, Vitamin D and diphosphonates with significant improvement on bone pain. Conservative treatment failed to halt disease progression and 2 out of seven pts with bone lesions are now requiring surgery. In our study, AVN of the bone is a frequent late complication of BMT causing significant morbidity. Its major incidence in children undergoing UD-BMT supports the hypothesis that both prolonged immunosoppressive therapy (steroid) and GvHD have a strong association with AVN.
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Emotional adaptation of children 2 1/2 years after stem cell transplantation M. Gü nter, T. Klingebiel (Tü bingen, Frankfurt, D) Objective: Adaptation processes of 8-12 years old children in single room treatment under isolation conditions during SCT had been assessed and were now compared with the emotional adaptation after 2 . years.
Methods: We assessed 30 children undergoing SCT in a prospective longitudinal design (t1 = 2 weeks before transplantation; t2 = 2 weeks after transplantation; t3 = 2 . years after transplantation, N(t3) = 15). Methods included diagnostic interviews, projective instruments and self rating questionnaires (depression, anxiety, extraversion, neuroticism, body image). Results: 1. Social adaptation was reported to be highly satisfactory after 2 . years. 2. In the standardised questionnaires the children showed significant differences to the normal population. 2 . years after SCT had taken place the children pointed out that they were extremely not anxious, not depressed, extraverted and they had very low scores in body differentiation. This "over-normalisation" with respect to the normal population was as extreme as during SCT. 3. In the scores of the projective Rorschach tests which encompassed deeper levels of self experience we could show a turning to inner processing of problems instead of externalisation and a more realistic attitude towards the illness. 4. Thematically the examination of sexual topics related to the illness and the treatment, the vulnerability of one's body, and anxieties to suffer from a relapse were prominent. Conclusion: The overall very good psychosocial adaptation of children after SCT was the result of very complex emotional processes which must be described on several levels of psychic organisation. In order to understand better the child's situation we have to look closely at these highly differentiated coping processes. Although most of the children seem to adapt very well we must have in mind that this is reached with much emotional effort.
